24 December 2015 - Eagle Pharmaceuticals, Inc. announced today that the U.S. FDA has approved docetaxel injection, non-alcohol formula for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

For more details, go to: http://investor.eagleus.com/press-release/eagle-pharmaceuticals-announces-fda-approval-docetaxel-injection-non-alcohol-formula